

Please type a plus sign (+) inside this box →

PTQ/SB/08A (10-96)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/688,871
				Filing Date	10-16-2003
				First Named Inventor	CZEKAJ
				Group Art Unit	1624
				Examiner Name	T.O. McKenzie <i>COLEMAN</i>
Sheet	1	of	2	Attorney Docket Number	DEAV/1999/S005 - US - CIP1

[illegible][illegible]

Examiner Signature	Brenda Coleman	Date Considered	Dec. 1, 2006
-----------------------	----------------	--------------------	--------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0851-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	10/686,871	
			Filing Date	10-16-2003	
			First Named Inventor	CZEKAJ	
			Group Art Unit	1824	
			Examiner Name	F.G. McKenzie COLEMAN	
Sheet	2	of	2	Attorney Docket Number	DEAV1999/S005 - US -CIP1

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ²	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
BC		ARISAWA, Mitsuhiro et al., Construction of Chiral 1,2-Cycloalkanopyrrolidines from L-Proline Using Ring Closing Metathesis (RCM), Chem. Pharm. Bull. (2000), 48(10), 1593-1596	
BC		ARISAWA, Mitsuhiro et al., Synthesis of Chiral Bicyclic Lactams Using Ring Closure Metathesis: Synthesis of (-)-Coniceine and (S)-Pyrrolam A, Synlett (1997), (10), 1179-1180 <i>duplicate</i>	
BC		WOLFF, Manfred, Burger's Medicinal Chemistry and Drug Discovery, 5ed., Vol. 1, John Wiley & Sons, 1995, pages 875-877. <i>duplicate</i>	
BC		BANKER, G.S., et al., et al., Modern Pharmaceuticals, 3ed., Marcel Dekker, Inc., New York, 1996, page 598 <i>duplicate</i>	
BC		HAN, William T. et al., Azetidin-2-One Derivatives as Inhibitors of Thrombin, Bioorganic & Medicinal Chemistry, Elsevier Scient Ltd, GB, vol. 3, no. 8, 1995, pages 1123-1143	
BC		HERBERT, Richard B. et al., Synthesis of (+)-Norrispoline, J. Chem. Res., Synop. (1982), (11), p. 299	
BC		NEUKOMM, G. et al., Zur Struktur von Hypercratin, einem weiteren Alkaloid aus Ruspolia Hypercrateriformis Organic-Natural-Products: Part 188: Structure of Hypercratine, Another Alkaloid of Ruspolia Hypercrateriformis, Planta Med. (1989), Vol. 48(4), 246-52 <i>duplicate</i>	
BC		OKADA, Midori et al., Fluoro-Lactonization of 4-Alkenoic Acid Derivatives with N-Fluoropentachloropyridinium Triflate, J. Fluorine Chem. (1997), 82(2), 157-161	
BC		ROESSLER, Felix et al., Ruspolia Hypercrateriformis M.R.: Isolation and Structure Elucidation of New Pyrrolidine Alkaloids, Helv. Chim. Acta (1978), Vol. 61, Fasc. 3, 1200-1206	
BC		SHAN, Daxian, et al., Prodrug Strategies Based on Intramolecular Cyclization Reactions, J. Pharmaceutical Sciences, 1997, 86, pages 765-767	

**

** Structures only

Examiner Signature	<i>Brenda Coleman</i>	Date Considered	Dec. 1, 2006
--------------------	-----------------------	-----------------	--------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.